Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

pidnarulex (CX-5461)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Senhwa Biosci

Drug class:

RNA polymerase 1 inhibitor

Related drugs:

‹

›

HRD	Breast Cancer	HRD	Breast Cancer	CX-5461 Sensitive: B - Late Trials CX-5461 Sensitive : B	CX-5461 Sensitive: B - Late Trials CX-5461 Sensitive : B
PALB2 mutation	Breast Cancer	PALB2 mutation	Breast Cancer	CX-5461 Sensitive: B - Late Trials CX-5461 Sensitive : B	CX-5461 Sensitive: B - Late Trials CX-5461 Sensitive : B
BRCA2 mutation	Breast Cancer	BRCA2 mutation	Breast Cancer	CX-5461 Sensitive: B - Late Trials CX-5461 Sensitive : B	CX-5461 Sensitive: B - Late Trials CX-5461 Sensitive : B
BRCA1 mutation	Breast Cancer	BRCA1 mutation	Breast Cancer	CX-5461 Sensitive: B - Late Trials CX-5461 Sensitive : B	CX-5461 Sensitive: B - Late Trials CX-5461 Sensitive : B
HRD	Ovarian Cancer	HRD	Ovarian Cancer	CX-5461 Sensitive: B - Late Trials CX-5461 Sensitive : B	CX-5461 Sensitive: B - Late Trials CX-5461 Sensitive : B
PALB2 mutation	Ovarian Cancer	PALB2 mutation	Ovarian Cancer	CX-5461 Sensitive: B - Late Trials CX-5461 Sensitive : B	CX-5461 Sensitive: B - Late Trials CX-5461 Sensitive : B
BRCA2 mutation	Ovarian Cancer	BRCA2 mutation	Ovarian Cancer	CX-5461 Sensitive: B - Late Trials CX-5461 Sensitive : B	CX-5461 Sensitive: B - Late Trials CX-5461 Sensitive : B
BRCA1 mutation	Ovarian Cancer	BRCA1 mutation	Ovarian Cancer	CX-5461 Sensitive: B - Late Trials CX-5461 Sensitive : B	CX-5461 Sensitive: B - Late Trials CX-5461 Sensitive : B
TP53 mutation	Multiple Myeloma	TP53 mutation	Multiple Myeloma	CX-5461 + VE-821 Sensitive: D – Preclinical CX-5461 + VE-821 Sensitive : D	CX-5461 + VE-821 Sensitive: D – Preclinical CX-5461 + VE-821 Sensitive : D